Revolution Medicines (RVMD) Expected to Announce Quarterly Earnings on Wednesday

Revolution Medicines (NASDAQ:RVMD) is anticipated to announce its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect the company to post earnings of ($2.04) per share and revenue of $1.7730 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Revolution Medicines (NASDAQ:RVMD) last issued its earnings results on Wednesday, May 6th. The company reported ($2.29) EPS for the quarter, missing analysts’ consensus estimates of ($1.83) by ($0.46). During the same period in the previous year, the business posted ($1.13) EPS. On average, analysts expect Revolution Medicines to post $-8 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Revolution Medicines Stock Performance

NASDAQ:RVMD opened at $187.53 on Monday. Revolution Medicines has a 12 month low of $34.00 and a 12 month high of $194.56. The company has a debt-to-equity ratio of 0.19, a current ratio of 6.80 and a quick ratio of 6.80. The firm has a market capitalization of $39.87 billion, a PE ratio of -26.52 and a beta of 1.37. The business’s fifty day moving average price is $172.57 and its 200 day moving average price is $134.97.

Analysts Set New Price Targets

Several research firms have recently issued reports on RVMD. Wedbush upped their price objective on Revolution Medicines from $181.00 to $192.10 and gave the stock an “outperform” rating in a research report on Thursday, July 23rd. Stifel Nicolaus reissued a “buy” rating on shares of Revolution Medicines in a research report on Monday, April 20th. Piper Sandler boosted their target price on Revolution Medicines to $172.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Sanford C. Bernstein assumed coverage on Revolution Medicines in a research note on Thursday, May 21st. They set a “market perform” rating and a $151.00 target price for the company. Finally, Needham & Company LLC upped their price target on Revolution Medicines from $235.00 to $236.00 and gave the company a “buy” rating in a report on Monday, July 20th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Revolution Medicines presently has a consensus rating of “Moderate Buy” and an average target price of $144.67.

Insider Activity

In other Revolution Medicines news, insider Stephen Michael Kelsey sold 4,175 shares of the company’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $156.12, for a total value of $651,801.00. Following the completion of the transaction, the insider owned 291,876 shares in the company, valued at $45,567,681.12. This represents a 1.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mark A. Goldsmith sold 10,020 shares of the firm’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $156.12, for a total value of $1,564,322.40. Following the transaction, the insider directly owned 267,330 shares in the company, valued at approximately $41,735,559.60. The trade was a 3.61% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 132,497 shares of company stock worth $21,470,486 over the last three months. Company insiders own 7.60% of the company’s stock.

Institutional Trading of Revolution Medicines

A number of large investors have recently made changes to their positions in the company. Global Retirement Partners LLC grew its stake in Revolution Medicines by 1,002.8% during the 4th quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock worth $32,000 after buying an additional 361 shares during the last quarter. Arax Advisory Partners acquired a new stake in shares of Revolution Medicines in the fourth quarter valued at approximately $38,000. Los Angeles Capital Management LLC acquired a new stake in shares of Revolution Medicines in the fourth quarter valued at approximately $59,000. Empowered Funds LLC purchased a new position in shares of Revolution Medicines during the fourth quarter worth approximately $77,000. Finally, Danske Bank A S purchased a new position in shares of Revolution Medicines during the third quarter worth approximately $98,000. 94.34% of the stock is owned by institutional investors and hedge funds.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.